Theme: Innovative Cancer Therapy for Tomorrow

Chemotherapy 2016

Chemotherapy 2016

OMICS International Conferences invites all the participants from all over the world to attend “2nd International Conference on Antimicrobial Agents and Chemotherapy” during June 06-07, 2016 at Dallas, USA which includes prompt Keynote presentations, Oral talks, Poster presentations and Exhibitions.

Chemotherapy 2016 will focus on the latest databases, curation and research done in each and every area of the cancer and its therapy which will help patients to get relief. Through this chemotherapy meeting it will offer a unique opportunity for participants, investigators globally to meet, network, and perceive new scientific interactions in transfusion symposiums.

Track 1: Antimicrobial Chemotherapy                                                                            

Antimicrobial chemotherapy is the clinical application of antimicrobial agents to treat infectious disease.

Related Conferences:

International Conference on Pancreatic and Colorectal Cancer March 29-30, 2016 Atlanta USA; 4th International Conference on Blood Malignancies and Treatment April 18-20, 2016 Dubai,UAE ; 2nd International Conference on Prostate Cancer and Treatment May 05-07, 2016 Chicago, USA; Experts Meeting on Gynecologic Oncology May 19-21, 2016 San Antonio, USA ; Cancer Diagnostics Conference & Expo June 13-15, 2016 Rome, Italy; International Conference on Oral, Mouth and Throat Cancer August 18-20, 2016 Portland, USA;  ICMMAAC 2016 : 18th International Conference on Medical Microbiology, Antimicrobial Agents and Chemotherapy, May 23 - 24, 2016, London, United Kingdom; Radiology in China, April 24-30, 2016, Xi'an and Shanghai, China; Swiss Congress of Radiology 2016, May 26-28, 2016, Bern, Switzerland; Cancer Survivorship Symposium: Advancing Care and Research – A Primary Care and Oncology Symposium, Jan 15-16, 2016, San Francisco, USA;  Cancer Center Business Summit, February 24 - 25, 2016, Phoenix, USA.

Track 2: Cancer Clinical Trials                                                                                                

Cancer clinical trials test many types of treatment such as new drugs, new approaches to surgery or radiation therapy, new combinations of treatments, or new methods. Cancer clinical trials are the first step in testing a new treatment in humans and their goal is to find better ways to treat cancer.

Related Conferences:

11th Asia-Pacific Oncologists Annual Meeting July 11-13, 2016 Kuala Lumpur, Malaysia; 10th Global Annual Oncologists Meeting July 11-13, 2016 Cologne, Germany; Global Summit on Melanoma and Carcinoma July 14-15, 2016 Brisbane,Australia; International Conference on Oral, Mouth and Throat Cancer August 18-20, 2016 Portland, USA; International Conference and Exhibition on Surgical Oncology September 01-03, 2016 Sao Paulo, Brazil; Accelerating Anticancer Agent Development and Validation Workshop, May 4-6, 2016, Bethesda, USA; The MASCC/ISOO Annual Meeting on Supportive Care in Cancer, June 23 - 25, 2016, Adelaide, Australia; EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, November 29 - December 2, 2016, Munich, Germany.

Track 3: Cancer Immunotherapy                                                                 

Biologic Response Modifiers (BRM), also called immunotherapy, is a type of treatment that mobilizes the body's immune system to fight cancer.   The therapy mainly consists of stimulating the immune system to help it do its job more effectively.  Tumor Vaccines also work to stimulate the body's immune system.

Related Conferences:

7th International Conference on Biomarkers & Clinical Research November 28-30, 2016 Baltimore, USA; International Conference on Mesothelioma November 03-04, 2016 Valencia, Spain; 4th Global Radiologists Annual Meeting March 17-18, 2016 London, UK; International Conference on Medical Imaging & Diagnosis May 09-10, 2016 Chicago, USA; International Conference on Nuclear Medicine & Radiation Therapy July 14-15, 2016 Cologne, Germany; EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, November 29 - December 2, 2016, Munich, Germany; The MASCC/ISOO Annual Meeting on Supportive Care in Cancer, June 23 - 25, 2016, Adelaide, Australia; Accelerating Anticancer Agent Development and Validation Workshop, May 4-6, 2016, Bethesda, USA; Cancer Center Business Summit, February 24 - 25, 2016, Phoenix, USA.

Track 4: Chemo Safety                                                                   

Precautions need to be taken to protect you and your caregivers from coming into contact with chemotherapy medicine. Chemotherapy leaves the body through urine, vomit, blood, stool, sweat, mucus and sexual fluids. Most chemotherapy medications will be out of your body in less than 48 hours.

Related Conferences:

5th International Conference on Radiology and Imaging September 19-20, 2016 Las Vegas, USA; 7th International Conference Biomarkers & Clinical Research November 28-30, 2016 Baltimore, USA; 4th Global Radiologists Annual Meeting March 17-18, 2016 London, UK; International Conference on Cervical Cancer September 22-23, 2016 Vienna, Austria; International Conference on Medical Imaging & Diagnosis May 09-10, 2016 Chicago, USA; International Conference on Nuclear Medicine & Radiation Therapy July 14-15, 2016 Cologne, Germany; ICMMAAC 2016 : 18th International Conference on Medical Microbiology, Antimicrobial Agents and Chemotherapy, May 23 - 24, 2016, London, United Kingdom; Radiology in China, April 24-30, 2016, Xi'an and Shanghai, China; Swiss Congress of Radiology 2016, May 26-28, 2016, Bern, Switzerland; Cancer Survivorship Symposium: Advancing Care and Research – A Primary Care and Oncology Symposium, Jan 15-16, 2016, San Francisco, USA;  Cancer Center Business Summit, February 24 - 25, 2016, Phoenix, USA.

Track 5: Chemo Side-effects

Side effects can range from fatigue and flu-like symptoms to hair loss and blood clotting problems. Because it's hard for doctors to predict how a child's body will react, all kids who undergo treatment for cancer are very closely monitored. Doctors weigh the amount and severity of side effects against the benefits of treatments.

Related Conferences:

International Conference on Cervical Cancer September 22-23, 2016 Vienna, Austria; 4th Global Radiologists Annual Meeting March 17-18, 2016 London, UK; International Conference on Nuclear Medicine & Radiation Therapy July 14-15, 2016 Cologne, Germany; International Conference on Mesothelioma November 03-04, 2016 Valencia, Spain; Swiss Congress of Radiology 2016, May 26-28, 2016, Bern, Switzerland; Cancer Survivorship Symposium: Advancing Care and Research – A Primary Care and Oncology Symposium, January 15-16, 2016, San Francisco, USA;  Cancer Center Business Summit, February 24 - 25, 2016, Phoenix, USA; Accelerating Anticancer Agent Development and Validation Workshop, May 4 - 6, 2016, Bethesda, USA; The MASCC/ISOO Annual Meeting on Supportive Care in Cancer, June 23 - 25, 2016, Adelaide, Australia.

Track 6: Chemo Treatment                                                                                     

The method of administration of chemo treatments along with the dose is determined by rigorous testing called clinical trials, which are done prior to the specific chemo drug being available for commercial use with patients.   During this testing process, scientists and doctors determine how specific chemo drugs are absorbed in the body and how they work. Sometimes stomach juices can destroy different chemicals, making some medications impossible to give as a pill. Other substances are found to have better anti-cancer action if given intravenously (needle in the vein).  Some medications can be given as an injection into the muscle and still others are absorbed when given directly into the bladder or the abdominal cavity.

Related Conferences:

International Conference on Pancreatic and Colorectal Cancer March 29-30, 2016 Atlanta USA; 4th International Conference on Blood Malignancies and Treatment April 18-20, 2016 Dubai,UAE ; 2nd International Conference on Prostate Cancer and Treatment May 05-07, 2016 Chicago, USA; Experts Meeting on Gynecologic Oncology May 19-21, 2016 San Antonio, USA; Cancer Diagnostics Conference & Expo June 13-15, 2016 Rome, Italy; Cancer Survivorship Symposium: Advancing Care and Research – A Primary Care and Oncology Symposium, Jan 15-16, 2016, San Francisco, USA; Cancer Center Business Summit, February 24 - 25, 2016, Phoenix, USA; Swiss Congress of Radiology 2016, May 26-28, 2016, Bern, Switzerland; Radiology in China, April 24-30, 2016, Xi'an and Shanghai, China; ICMMAAC 2016 :18th International Conference on Medical Microbiology, Antimicrobial Agents and Chemotherapy, May 23 - 24, 2016, London, UK.

Track 7: Chemoprotective Agents                                                                                           

Chemoprotective agents are drugs that are used with certain types of chemotherapy to protect the body from or minimize the side effects of the chemotherapy.  Common chemoprotective agents include amifostine, dexrazoxane, and mesna.

Related Conferences:

11th Asia-Pacific Oncologists Annual Meeting July 11-13, 2016 Kuala Lumpur, Malaysia; 10th Global Annual Oncologists Meeting July 11-13, 2016 Cologne, Germany; Global Summit on Melanoma and Carcinoma July 14-15, 2016 Brisbane,Australia; International Conference on Oral, Mouth and Throat Cancer August 18-20, 2016 Portland, USA; International Conference and Exhibition on Surgical Oncology September 01-03, 2016 Sao Paulo, Brazil; The MASCC/ISOO Annual Meeting on Supportive Care in Cancer, June 23 - 25, 2016, Adelaide, Australia; EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, November 29 - December 2, 2016, Munich, Germany; Accelerating Anticancer Agent Development and Validation Workshop, May 4 - 6, 2016, Bethesda, USA; Swiss Congress of Radiology 2016, May 26-28, 2016, Bern, Switzerland; Cancer Survivorship Symposium: Advancing Care and Research – A Primary Care and Oncology Symposium, Jan 15-16, 2016, San Francisco, USA.

Track 8: Chemotherapy Agents                                                         

Alkylating agents are most active in the resting phase of the cell. Plant alkaloids are chemotherapy treatments derived made from certain types of plants.  Antitumor antibiotics are chemo treatments made from natural products produced by species of the soil fungus Streptomyces. Antimetabolites are types of chemotherapy treatments that are very similar to normal substances within the cell. Toposiomerase inhibitors are types of chemotherapy drugs that interfere with the action of topoisomerase enzymes (topoisomerase I and II).

Related Conferences:

7th International Conference on Biomarkers & Clinical Research November 28-30, 2016 Baltimore, USA; 11th Asia-Pacific Oncologists Annual Meeting July 11-13, 2016 Kuala Lumpur, Malaysia; 4th Global Radiologists Annual Meeting March 17-18, 2016 London, UK; International Conference on Medical Imaging & Diagnosis May 09-10, 2016 Chicago, USA; International Conference on Nuclear Medicine & Radiation Therapy July 14-15, 2016 Cologne, Germany; International Conference on Pancreatic and Colorectal Cancer March 29-30, 2016 Atlanta USA; Radiology in China, April 24-30, 2016, Xi'an and Shanghai, China; Swiss Congress of Radiology 2016, May 26-28, 2016, Bern, Switzerland; Cancer Survivorship Symposium: Advancing Care and Research – A Primary Care and Oncology Symposium, Jan 15-16, 2016, San Francisco, USA;  Cancer Center Business Summit, February 24 - 25, 2016, Phoenix, USA; Accelerating Anticancer Agent Development and Validation Workshop, May 4 - 6, 2016, Bethesda, USA.

Track 9: Chemotherapy Protocols                                                          

Chemotherapy protocols strive to maximize the elimination of cancer cells while minimizing the negative effects that these protocols have on healthy cells. Much progress in developing successful chemotherapy protocols has been made, including the identification of many different types of cancer and the corresponding development of effective chemotherapy protocol solutions. But there is still much work to be done.

Related Conferences:

11th Asia-Pacific Oncologists Annual Meeting July 11-13, 2016 Kuala Lumpur, Malaysia; 10th Global Annual Oncologists Meeting July 11-13, 2016 Cologne, Germany; Global Summit on Melanoma and Carcinoma July 14-15, 2016 Brisbane,Australia; International Conference on Oral, Mouth and Throat Cancer August 18-20, 2016 Portland, USA; International Conference and Exhibition on Surgical Oncology September 01-03, 2016 Sao Paulo, Brazil; Experts Meeting on Gynecologic Oncology May 19-21, 2016 San Antonio, USA ; Cancer Survivorship Symposium: Advancing Care and Research – A Primary Care and Oncology Symposium, Jan 15-16, 2016, San Francisco, USA;  Cancer Center Business Summit, February 24 - 25, 2016, Phoenix, USA; The MASCC/ISOO Annual Meeting on Supportive Care in Cancer, June 23 - 25, 2016, Adelaide, Australia; EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, November 29 - December 2, 2016, Munich, Germany; ICMMAAC 2016 : 18th International Conference on Medical Microbiology, Antimicrobial Agents and Chemotherapy, May 23 - 24, 2016, London, UK.

Track10: Chemotherapy Resistance

Chemotherapy resistance occurs when cancers that have been responding to a therapy suddenly begin to grow.The development of drug resistance is one reason that drugs are often given in combination.  It is thought that this may reduce the incidence of developing resistance to any one drug.  Often, if a cancer becomes resistant to one drug or group of drugs, it is more likely that the cancer may be resistant to other drugs.  This is why it is very important to select the best possible treatment protocol FIRST.  In other words, when treating cancer, one should use the best weapon when there is the smallest possibility of chemotherapy resistance.

Related Conferences:

4th International Conference on Blood Malignancies and Treatment April 18-20, 2016 Dubai,UAE ; 2nd International Conference on Prostate Cancer and Treatment May 05-07, 2016 Chicago, USA; Experts Meeting on Gynecologic Oncology May 19-21, 2016 San Antonio, USA ; Cancer Diagnostics Conference & Expo June 13-15, 2016 Rome, Italy; International Conference on Oral, Mouth and Throat Cancer August 18-20, 2016 Portland, USA;  ICMMAAC 2016 : 18th International Conference on Medical Microbiology, Antimicrobial Agents and Chemotherapy, May 23 - 24, 2016, London, United Kingdom; Radiology in China, April 24-30, 2016, Xi'an and Shanghai, China; Swiss Congress of Radiology 2016, May 26-28, 2016, Bern, Switzerland; Cancer Survivorship Symposium: Advancing Care and Research – A Primary Care and Oncology Symposium, Jan 15-16, 2016, San Francisco, USA;  Cancer Center Business Summit, February 24 - 25, 2016, Phoenix, USA; International Conference on Pancreatic and Colorectal Cancer March 29-30, 2016 Atlanta USA.

Track11: Chemotherapy Types

Chemotherapy encompasses a wide variety of therapy treatments.  Terms such as "adjuvant," "neoadjuvant," "consolidation," and "palliative" often add to the confusion surrounding chemotherapy if not properly defined and explained.  The purpose of this page is to increase the level of understanding about various chemotherapy protocols currently used.

Related Conferences:

10th Global Annual Oncologists Meeting July 11-13, 2016 Cologne, Germany; Global Summit on Melanoma and Carcinoma July 14-15, 2016 Brisbane,Australia; International Conference on Oral, Mouth and Throat Cancer August 18-20, 2016 Portland, USA; International Conference and Exhibition on Surgical Oncology September 01-03, 2016 Sao Paulo, Brazil; Accelerating Anticancer Agent Development and Validation Workshop, May 4-6, 2016, Bethesda, USA; The MASCC/ISOO Annual Meeting on Supportive Care in Cancer, June 23 - 25, 2016, Adelaide, Australia; EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, November 29 - December 2, 2016, Munich, Germany; 11th Asia-Pacific Oncologists Annual Meeting July 11-13, 2016 Kuala Lumpur, Malaysia.

Track12: Hormone Therapy

The use of hormone therapy to treat cancer is based on the observation that receptors for specific hormones that are needed for cell growth are on the surface of some tumor cells.  Hormone therapy can work by stopping the production of a certain hormone, blocking hormone receptors, or substituting chemically similar agents for the active hormone, which cannot be used by the tumor cell.  The different hormone therapy types are categorized by their function and/or the type of hormone that is effected.

Related Conferences:

Global Summit on Melanoma and Carcinoma July 14-15, 2016 Brisbane,Australia; International Conference on Oral, Mouth and Throat Cancer August 18-20, 2016 Portland, USA; International Conference and Exhibition on Surgical Oncology September 01-03, 2016 Sao Paulo, Brazil; Accelerating Anticancer Agent Development and Validation Workshop, May 4-6, 2016, Bethesda, USA; The MASCC/ISOO Annual Meeting on Supportive Care in Cancer, June 23 - 25, 2016, Adelaide, Australia; EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, November 29 - December 2, 2016, Munich, Germany; 11th Asia-Pacific Oncologists Annual Meeting July 11-13, 2016 Kuala Lumpur, Malaysia; 10th Global Annual Oncologists Meeting July 11-13, 2016 Cologne, Germany.

Track13: Targeted Therapy

Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules ("molecular targets") that are involved in the growth, progression, and spread of cancer. Targeted cancer therapies are sometimes called "molecularly targeted drugs," "molecularly targeted therapies," "precision medicines," or similar names.

Related Conferences:

International Conference and Exhibition on Surgical Oncology September 01-03, 2016 Sao Paulo, Brazil; Accelerating Anticancer Agent Development and Validation Workshop, May 4-6, 2016, Bethesda, USA; The MASCC/ISOO Annual Meeting on Supportive Care in Cancer, June 23 - 25, 2016, Adelaide, Australia; EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, November 29 - December 2, 2016, Munich, Germany; 11th Asia-Pacific Oncologists Annual Meeting July 11-13, 2016 Kuala Lumpur, Malaysia; 10th Global Annual Oncologists Meeting July 11-13, 2016 Cologne, Germany; Global Summit on Melanoma and Carcinoma July 14-15, 2016 Brisbane,Australia; International Conference on Oral, Mouth and Throat Cancer August 18-20, 2016 Portland, USA.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OMICS International Conferences invites all the participants from all over the world to attend ‘2nd International Conference on Antimicrobial Agents and Chemotherapy’during June 06-07, 2016 at Dallas, USA  which includes prompt Keynote presentations, Oral talks, Poster presentations and Exhibitions.

Chemotherapy 2016 will focus on the latest databases, curation and research done in each and every area of the cancer and its therapy which will help patients to get relief. Through this chemotherapy meeting it will offer a unique opportunity for participants, investigators globally to meet, network, and perceive new scientific interactions in transfusion symposiums. Chemotherapy meetings 2016 will comprise various leading keynote speakers and session speakers who will be delivering their speech on the current research topics of anti-cancer drug development, clinical research on cancer, immunology and vaccines. The young researchers and the student participants will gain the opportunity to grab the Best Poster Award by presenting their work as a poster presentation and Young Researcher Forum in this melanin meeting.

OMICS International organizes a conference series of 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Why to attend???

With members from around the world focused on learning about Chemotherapy and its advances; this is your best opportunity to reach the largest assemblage of participants from the Chemotherapy community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Chemotherapy are hallmarks of this conference.

Target Audience:

  • Chemotherapy Students, Scientists
  • Chemotherapy Researchers
  • Chemotherapy Faculty
  • Medical Colleges
  • Chemotherapy Associations and Societies
  • Business Entrepreneurs
  • Training Institutes

Summary of  Chemotherapy Conference (Overall Market of Chemotherapy with Statistics)

Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various cancer conditions, growing popularity of advance therapies (biological and targeted drug therapies), patents expiration of leading drugs along with commercialization of biosimilars are the few factors driving the growth of Chemotherapy drugs market. However, high cost involved in new drug development coupled with threat of failure and adverse effects associated with Chemotherapy drugs therapies would restrain the growth of the market. Commercialization of advanced therapeutics such as targeted and immunotherapies would reduce the negative influence of restraints and fuel the market growth.

The Chemotherapy drugs market is expected to reach at $111.9 billion by 2020. Patent expiration of key cancer drugs such as Herceptin, Erbitux, Rituxan and Avastin, is expected to boost the growth of cancer biosimilars market by 2020. Going further, the biological therapies are expected to dominate the market by 2020, due to their high efficacy, target specific action and less toxicity. Blood cancer drugs market was the largest revenue generating segment in 2016 owing to the high cost of drugs (immunotherapies) used for the treatment of blood cancer.

Geographically, North America, dominates the market followed by Europe. North America accounted for about ~38% share in the overall oncology drugs market in 2016 owing to the heavy investments by multinational companies in research and development of cancer drugs, particularly immune therapeutics, favorable reimbursement policies, and high adoption rate of immunotherapies. On the other hand, Asia-Pacific market would grow at the promising CAGR of 8.7% during the forecast period. Such high growth rate is majorly due to increasing awareness towards advanced therapies namely immunotherapies and increase in per capita healthcare spending.

Why it’s in Dallas, USA?

Chemotherapy confers a large burden in the United States. Several evidence-based interventions are available to reduce the incidence, morbidity, and mortality from these cancers. The National Comprehensive Chemotherapy Control Program (NCCCP) is uniquely positioned to implement these interventions in the US population. It is estimated that there will be about 91,000 new cases diagnosed and approximately 28,000 deaths from cancer in the United States during 2016.

Members Associated with Chemotherapy Research

Chemotherapy research associated members in Dallas are about 418, in USA 5684 members and worldwide about 10214 research members.

Hospitals Associated with Chemotherapy Research

Major Chemotherapy associated hospitals in Dallas are around 2% when compared to worldwide.

Hospitals in Dallas and USA are:

Dallas Cancer Care

Baylor University Medical Center

UT Southwestern Medical Center

Texas Health Presbyterian Hospital Dallas

Medical City Dallas Hospital

Plaza Medical Center

Texas Health Harris Methodist Hospital Fort Worth

Medical Center of Plano

Parkland Memorial Hospital

Baylor All Saints Medical Center at Fort Worth

Societies Associated with Chemotherapy Research

In world there are about 9,685 societies which are specifically associated with Gynecologic oncology, in which 1289 societies are from USA and the remaining 269 societies are from Dallas.

 

  • American Chemotherapy society
  • National cancer institute
  • Society of Chemotherapy
  • International Chemotherapy society
  • American college of  Phlebology
  • American congress of  Chemotherapy
  • Asian Society of  Chemotherapy
  • Chemotherapy Group
  • Northern Chemotherapy Centre
  • Queensland Centre for Chemotherapy

Industries Associated with Chemotherapy Research

Industries associated with Chemotherapy over all world is about 85% in which 12% of industries are in USA and in Dallas about 3%.

 

  • Johnson & Johnson
  • Novartis
  • Roche
  • Pfizer
  • Sanofi
  • Merck
  • Bristol-myers squibb
  • Eli Lilly
  • Celgene
  • Takeda
  • AstraZeneca
  • Merck & Co.
  • Amgen
  • Bayer
  • Otsuka
  • Pharmacyclics
  • Incyte

Universities Associated with Chemotherapy Research

Chemotherapy associated universities in world are about 3284, in USA 612 universities.

The University of Texas at Austin

Texas A&M University

Rice University

University of Houston

University of North Texas

Texas Tech University

The University of Texas at Dallas

Baylor University

Southern Methodist University

The University of Texas at Arlington

Texas State University

The University of Texas MD Anderson Cancer Center

The University of Texas at San Antonio

The University of Texas at El Paso

The University of Texas Medical Branch at Galveston

The University of Texas Health Science Center at San Antonio

Baylor College of Medicine

Lamar University

Sam Houston State University

Texas Christian University

University of Texas Southwestern Medical Center

Trinity University

Stephen F. Austin State University

Texas Tech University Health Sciences Center

Texas Woman's University

St. Edward's University

The University of Texas Health Science Center at Houston

Texas A&M University-Corpus Christi

Texas Southern University

Abilene Christian University

Tarleton State University

Texas A&M International University

Angelo State University

Southwestern University

West Texas A&M University

University of Houston-Clear Lake

Texas A&M University-Kingsville

The University of Texas-Pan American

South Texas College of Law

Midwestern State University

Prairie View A&M University

The University of Texas at Brownsville

St. Mary's University

University of Houston-Downtown

University of Dallas

The University of Texas at Tyler

Dallas Baptist University

University of the Incarnate Word

LeTourneau University

Houston Baptist University

University of Mary Hardin-Baylor

Southwestern Adventist University

Our Lady of the Lake University

Texas A&M University-Commerce

Austin College

Texas A&M University at Galveston

Concordia University Texas

The University of Texas of the Permian Basin

Hardin-Simmons University

University of St. Thomas

McMurry University

Sul Ross State University

Texas Wesleyan University

Wayland Baptist University

University of Houston-Victoria

Schreiner University

Lubbock Christian University

Texas A&M University-Texarkana

East Texas Baptist University

Southwestern Assemblies of God University

Huston-Tillotson University

Jarvis Christian College

Wiley College

Texas Lutheran University

Howard Payne University

Amberton University

Paul Quinn College

Dallas Christian College

The University of Texas Health Science Center at Tyler

Texas College

Arlington Baptist College

College of Biblical Studies

Baptist University of the Americas

Market Value on Chemotherapy Research

The global Chemotherapy market in 2010 was valued at $54bn, an increase of 5.1% over the previous year‘s sales of $51.3bn, and is forecasted to grow at a CAGR of 6.9% from 2010–16, reaching $81bn in 2016.

  • Collectively, the seven major markets (US, 5EU, and Japan) represented 79.1% (or $43bn) of in the Chemotherapy market  in 2016. In terms of size, the US dominated the Chemotherapy market , with 2016 sales of $21bn and a market share of 38.5%.
  • The Chemotherapy market  is becoming increasingly competitive, with two therapeutic classes, namely antineoplastics and cytostatic hormonal treatments, dominating this sector. Collectively, the leading 10 brands accounted for almost 58.2% (or $31.4bn) of the Chemotherapy market  in 2016.
  • In 2016 antineoplastics was the leading drug class in the Chemotherapy market . The global antineoplastic market was valued at $46bn in 2016 at a year-on-year (Y-o-Y) growth of 7.3%. The major drugs that contributed to the 2016 sales in the antineoplastic category were Roche‘s Avastin (bevacizumab) at $6.2bn, Herceptin (trastuzumab) at $5.2bn, and MabThera (rituximab) at $5.1bn, with Y-o-Y sales growth of 3.8%, 3.1%, and 3.3% respectively.
  • The cytostatic hormonal market registered 2016 sales of $8bn at a Y-o-Y decline of 6.5%. AstraZeneca‘s Arimidex (anastrozole) and Novartis‘s Femara (letrozole) led this class, reaching sales of $1.5bn and $1.3bn respectively in 2016

Market Growth of Chemotherapy Research in the last and upcoming ten years

TechNavio's analysts forecast the Global Chemotherapy market  to grow at a CAGR of 12.47% over the period 2013-2018. One of the key factors contributing to this market growth is the increase in prevalence of Chemotherapy . The Global Chemotherapy market has also been witnessing the emergence of personalized medicines. However, the increase in use of CAM could pose a challenge to the growth of this market. In next ten years as population ages, the number of people diagnosed with cancer is expected to be double. According to the American Cancer Society, cancer accounts for every 1 of every 4 in U.S deaths, for women it is one in three .The volume of cancer services continues to grow. Radiation therapy by 3%,infusion therapy by 7% ; Gynecologic services by 10%(annually).With earlier detection,cancer patients will be identified earlier with improvements in chemotherapy,patients will be able to tolerate more treatments, all of which will result in more treatments per patient and more lives saved.

Fund Allotment to Chemotherapy Research

Fund allotted to the individual types of Chemotherapy research in Dollars for Ovarian, Cervical and Uterine cancers 147$, 119$ and 59$ in which Cervical cancer is funded majorly.

Statistics of Physicians, Researchers and Academicians working on Chemotherapy

San Antonio's Biosciences industry employs over 100,000 people. The largest areas of research are conducted by institutes in or around the South Texas Medical Center. These include the Chemotherapy division of one of the world's top five biotechnology firms, the world's largest Phase I clinical trials program for Chemotherapy, and the new $200 million woman’s Cancer Research Institute. Dallas also houses the world's largest genomics computing cluster and the state's public bank for stem cell-rich umbilical cord blood.

Products manufactured by the industry related Chemotherapy Research

Market Value:

 

  • Neosar (Cyclophosphamide)- manufactured by Roxane Laboratories Inc and the market value is17.06$
  • Paraplat (Carboplatin)-manufactured by Bristol-Myers Squibb Company and the market value is128$
  • Platinol (Cisplatin)-manufactured by Bristol-Myers Squibb Company and the market value is15.3$
  • Gemzar (Gemcitabine Hydrochloride)-manufactured by Eli Lilly and Company and the market value is26.1$
  • Clafen (Cyclophosphamide)-manufactured by Selleckchem and the market value is150$

 

Chemotherapy-2015

Over thousands of scholars from the field of Chemotherapy stepped away from their nations last Tuesday, August 2nd, 2015to take part in an ostentatious event “International Conference on Antimicrobial Agents and Chemotherapy” August 04-06, 2015, in Valencia, Spain. The conference was organized around a single theme “Emerging techniques and advancements in the field of chemotherapy which comprised of 06 tracks with knowledge oriented presentations igniting young minds in the crowd.

The Conference provided a rostrum for interaction among keynotes, chair & co-chairs, plenary speakers, poster presentees, young research fellows & delegates and to share their experiences, ideas & research, thus helping to generate a new way of looking at Cancer treatments.

Conference began with the welcome message given by our moderator Dr. Emil Toma, University of Montreal, USA, followed by a Keynote series of well-known speakers:

  • Dr. Emil Toma, University of Montreal, USA.
  • Dr. Didier Coquoz, Copexis, Switzerland.
  • Dr. Hiroyuki Osada, RIKEN Center for Sustainable Resource Science, Japan.

The session was chaired by Dr. Emil Toma, University of Montreal, USA, preceded with paramount Oral Presentations. The Conference also witnessed an amalgamation of eminent speakers like:

  • Junjun Qiu, Obstetrics and Gynecology Hospital of Fudan University, China.
  • Helene Castel, Universite de Rouen, France
  • Paula Sabbo Bernado, Brazilian National Cancer Institute, Brazil.

The Conference also provided a platform for a grandiose Workshop by:

  • Isabel Portero Sanchez, Universidad Complutense & BIOHOPE Scientific Solutions, Spain
  • Dirk Buscher, Gri-Cel S.A. Spain
  • Eva Martin Becerra, Gradocell& IMMPULSO Medical Sciences, Spain

The second day session was chaired and Keynote speech was given by:

  • Dr. Hiroyuki Osada, RIKEN Center for Sustainable Resource Science, Japan

The session was preceded by Oral Presentations by:

  • Dr. Hiroyuki Osada, RIKEN Center for Sustainable Resource Science, Japan
  • Dr. Minoru Yoshida, RIKEN Center for Sustainable Resource Science, Japan
  • Natalia Martins, Polytechnic Institute of Braganca, Portugal

A Global Platform was given to students to explore their research work under the category Young Research Forum:

  • Bin Li, University of Hong Kong, China
  • Wen WenXu, University of Hong Kong, China
  • Natalia Martins, Polytechnic Institute of Braganca, Portugal
  • Maude Loignon, University of Montreal, Canada

Past Reports  Proceedings  Gallery  

Radiology-2015

OMICS International 3rd International Conference on Radiology & Imaging at Toronto Airport Marriott Hotel, Toronto, Canada during August 24-26, 2015 was organized with a focus on Critical Review on “Advanced Trends in Radiology and Imaging” was a great success where eminent keynote speakers from various reputed institutions made their resplendent presence and addressed the gathering.

Radiology-2015 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various newfangled topics related to the field of Radiology & Imaging.

Radiology-2015 Organizing Committee would like to thank the Moderator of the conference, Dr.Sangeeta Taneja, Indraprastha Apollo Hospitals, India who contributed a lot for the smooth functioning of this event.

OMICS Group International would like to convey a warm gratitude to all the Honorable guests and Keynote Speakers of Radiology-2015:

Richard P Hill, University of Toronto, Canada

Mark G Benz, Engineering Horizons International, USA

Radim Jancalek, St. Anne’s University Hospital, Czech Republic

Mitchell S Albert, Lakehead University, Canada

OMICS International, on behalf of the conference, appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavors.

OMICS International also took the privilege of felicitating Radiology-2015 Organizing Committee, Editorial Board Members of OMICS Journal of Radiology and Journal of Nuclear Medicine and Radiation Therapy, Keynote Speakers, Chair and Co-Chairs and Moderator whose support made conference a great success.

With the enormous feedback from the participants and supporters of Radiology-2015, OMICS International Conferences is glad to announce                  


Past Reports  Proceedings  Gallery  

Cancer Summit 2015

OMICS Group’s 5th Asia-Pacific Summit on Cancer Therapy at Park Regis Brisbane, Australia during July 20-22, 2015 was organized with a focus on "Forum for a world without cancer” was a great success where eminent keynote speakers from various reputed institutions made their resplendent presence and addressed the gathering.

Cancer Summit-2015 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various newfangled topics related to the field of cancer.

Cancer Summit-2015 Organizing Committee would like to thank the Moderator of the conference, Dr. Rupinder Kaur Kanwar, Deakin University, K who contributed a lot for the smooth functioning of this event.

OMICS Group International would like to convey a warm gratitude to all the Honorable guests and Keynote Speakers of Cancer Summit-2015:

Jagat R Kanwar, Deakin University, Australia

Kwok-nam Leung, The Chinese University of Hong Kong, Hong Kong

Izhak Haviv, Bar Ilan University, Israel

Pascal H G Dujif, University of Queensland, Australia

Veronica J James, Australian National University, Australia

OMICS Group, on behalf of the conference, congratulates the Best Poster awardees for their outstanding performance and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavors. We would like to thank the Poster Competition Judge Dr. Izhak Haviv, Bar Ilan University, Israel for his valuable time.

Best Poster Winners:

OMICS Group also took the privilege of felicitating Cancer Summit-2015 Organizing Committee, Editorial Board Members of Journals of Cancer Science & Therapy, Journal of Carcinogenesis & Mutagenesis and Journal of Integrative Oncology, Keynote Speakers, Chair and Co-Chairs and Moderator whose support made conference a great success.

With the enormous feedback from the participants and supporters of Cancer Summit-2015, OMICS Group Conferences is glad to announce      


Past Reports  Proceedings  Gallery  

Prostate Cancer-2015

Prostate Cancer-2015 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various newfangled topics related to the field of prostate. Qun Lu from East Carolina University, USA presented a paper on “Urine biomarkers for prostate cancer detection”; Veronica J James from Australian National University, Australia presented a paper on “Why wait till it is too late”; Taisei Nomura from Osaka University, Japan presented a paper on “Establishment of prostate cancer and benign prostatic hyperplasia PDX (patient-derived xenograft) in super-SCID mice”; Jiao Zhang from East Carolina University, USA presented a paper on “Development of prostatic exosomal protein (PSEP) lateral flow chromatographic strips for detection of chronic prostatitis”; Joanna Dulinska-Litewka from Jagiellonian University Medical College, Poland presented a paper on “Increased AKT signaling resulting from the loss of androgen responsiveness in prostate cancer”; Fahri Saatcioglu from University of Oslo, Norway presented a paper on “Divergent androgen regulation of unfolded protein response pathways drives prostate cancer”; Steve Assinder from Andrology Research Group, Australia presented a paper on “Oxytocin in prostate pathology. Is there a sinister side to the hormone of love”; Nathalie Picollet-D’hahan from CEA/DSV/iRTSV/BGE/Biomics, France presented a paper on “Emerging nano and microtechnologies in prostate cancer research: New tools for diagnosis & biomarkers discovery”.

Prostate Cancer-2015 dealt with the diagnosis, prevention, and treatment of diseases of the Prostate, Benign Prostatic Hyperplasia, Prostatitis, Radical Prostatectomy including Prostate Cancer side effects and management.

Dr. Lucia Languino, Thomas Jefferson University, USA conducted a workshop on Molecular mechanisms of prostate cancer progression on June 22, 2015, in connection with this conference and as a curtain raiser to the topic.

Poster presentations were presented by students and the best posters were awarded to Charlotte Lavallee from University of Copenhagen, Denmark and Nanami Kikuchi from University of Central Florida, USA

All the papers presented at the Prostate Cancer-2015 will be published in the proceedings of the Journal of Cancer Science and Therapy

 


Past Reports  Proceedings  Gallery  

Breast Cancer-2015

Thanks to all of our wonderful speakers, conference attendees and Sponsors, Breast Cancer-2015 Conference was our best ever!

World Congress on Breast Cancer, hosted by the OMICS Group was held during August 03-05, 2015 Birmingham, UK at Hilton Birmingham Metropole Hotel, Birmingham, UK with the theme “New Discoveries for Better Diagnosis and Treatments for Breast Cancer and to bring Awareness”. Benevolent response and active participation was received from the Editorial Board Members of OMICS Group Journals as well as from the Professors, Surgeons, Oncologists, Biostatisticians, Healthcare Professionals, Industry experts, Researchers and Students from the fields Breast Cancer-2015, who made this event successful.

The meeting was carried out through various sessions, in which the discussions were held on the following major scientific tracks:

Biology of Breast Cancer

Breast Cancer Tests: Screening, Diagnosis and Monitoring

HER2 Positive and Other Types of Breast Cancers

Breast Cancer Therapy

Chemotherapy for Breast Cancer

Breast Cancer Immunotherapy & Radiation Therapy

Innovative Therapeutic Approaches in Breast Cancer

Breast Cancer Treatment Side Effects

Optimal Breast Cancer Pathology – Organization

The conference was initiated with a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The list included:

Shahla Masood

University of Florida College of Medicine-Jacksonville, USA

Raj Kumar

The Commonwealth Medical College, USA

Tibor Tot

European Society of Pathology, Sweden

Amila Orucevic

The University of Tennessee Medical Center, USA 

Yvonne Paterson

University of Pennsylvania, USA

Aysegul A. Sahin

The University of Texas MD Anderson Cancer Center, USA

Robert-Alain Toillon

Universite Lille 1, France

Philippa D. Darbre

University of Reeding, UK

S Sahni

Indraprastha Apollo Hospital, India

Peter Weightman

University of Liverpool, UK

Esmaeil Akbari

Shahid Beheshti University of Medical Sciences, Iran

Lei Huo

The University of Texas MD Anderson Cancer Center, USA

Stephen Assinder

University of Sydney, Australia

 

 

 


Past Reports  Gallery  

Cancer Science-2014

OMICS Group’s 4th World Congress on Cancer Science & Therapy was held during October 20-22, 2014 at DoubleTree by Hilton Hotel Chicago - North Shore Conference Center, Chicago, USA.

Generous response and active participation was received from the Editorial Board Members of OMICS Group Journals, scientists, researchers, as well as experts in the cancer research, leaders from the fields of Cancer Therapy, and students from diverse groups, who made this conference one of the most successful and productive events in 2014 from OMICS Group.

The conference proceedings were carried out through effectual keynote lectures by:

Dr. Peter Weightman, University of Liverpool, UK
Dr. Sudhakar Akul Yakkanti, SRI International, USA
Dr. Jeffrey B. Ulmer, Novartis Vaccines & Diagnostics, USA
Dr. Reza Hakkak, University of Arkansas for Medical Sciences, USA

This annual conference brought together eminent experts from different countries in which many modern issues were discussed in depth to provide up-to-date information to the world. On the other hand, the meeting provided a good platform to share their ideas and experiences in the field of cancer therapy.

The conference was greeted by the welcome message by our moderators Juan Jose Marugan, National Institutes of Health, USA and Bernard Friedenson, University of Illinois, USA, and welcomed Honorable guests Sudhakar Akul Yakkanti, SRI International, USA, Anupam Bishayee, California Northstate University, USA, and Reza Hakkak, University of Arkansas for Medical Sciences, USA.

We sincerely acknowledge all the organizing committee members, moderators, chair and co-chairs, editorial board members, speakers, delegates for their gracious presence, and support in making this event successful. OMICS Group has taken the privilege of felicitating Cancer Science-2014 Organizing Committee Members, Editorial Board Members and Keynote Speakers who supported for the success of this event. OMICS Group, on behalf of the conference exhibitors congratulates the Best Poster awardees for their outstanding performance in the field of Cancer Science & Therapy and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavors.

The esteemed guests, Keynote speakers, well-known researchers and delegates shared their innovative research and vast experience through their fabulous presentations at the podium of grand Cancer Science-2014. We are glad to inform that all accepted abstracts for the conference have been indexed in OMICS Group Journal of Cancer Science & Therapy and Journal of Carcinogenesis & Mutagenesis as a special issue. Basing on the conference theme, "Enhanced diagnosis, treatment and management of different cancers”, the speakers recommended organizing the conference in the field of Cancer Science and Therapy in the coming years also.

We are obliged to various experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums. We sincerely thank the Organizing Committee Members for their gracious presence, support, and assistance towards the success of Cancer Science-2014. With the unique feedback from the conference, OMICS Group would like to announce its "5th World Congress on Cancer Science & Therapy" to be held during October 20-22, 2014 in Chicago, USA.


Past Reports  Gallery  

Radiology-2013

OMICS Group organized an International Conference on Radiology and Imaging which was held during August 14-16, 2013 in Holiday Inn Chicago Northshore, USA. The congress was organized with the goal of providing a platform for the future development of the discipline. Generous response and active participation was received from the Editorial Board Members of OMICS Group Journals as well as from scientists, researchers and NIH, students who made this conference as one of the most successful events in 2013 from OMICS Group.

The conference was carried out through the following sessions:

  • Acquisition of Radiological Images
  • Interventional Radiology Procedures
  • Applications of Radiography
  • Disorders of Interventional Radiology
  • Radiation Therapy
  • Radiology for the Non-Radiologist
  • Advances in Imaging
  • Diagnostic Imaging Techniques
  • Radiopharmaceuticals
  • PET/MRI versus PET/CT Hybrid

The main theme of this Conference was "An Insight into Advanced Methodologies in Radiology".

The conference was initiated with a series of invited lectures delivered by both Honorable Guests and members of the Keynote forum.

Keynote speakers:

  • Ravinder Reddy, University of Pennsylvania, USA
  • Hollis Potter, Hospital for Special Surgery, USA
  • Xiaohong Zhou, University of Illinois, USA

Some of the eminent speeches were given by:

  • Jiang Du, University of California, USA
  • Michael L. Goris, Stanford University School of Medicine, USA
  • Hua Guo, Tsinghua University School of Medicine, China
  • Morio Sato, Wakayama Medical University, Japan
  • Shuo li, GE Healthcare, Canada

Dr. David Cheng, Yale University, USA, acted as a moderator and helped in making this conference a huge success.

All accepted abstracts have been indexed in OMICS Journal of Radiology as a special issue.

With a wish to deliver a similar rostrum to the scientific community, we would like to announce 2nd International Conference on Radiology & Imaging during September 08-09, 2014 at Raleigh, North Carolina, USA.


Past Reports  Gallery  

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date December 08-09, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity
Poster Opportunity Available

Conferenceseries Destinations


Mail us at

Drop us an email for Program enquiry.
chemotherapy@insightconferences.com
Sponsors / Exhibiting / Advertising.
General Queries.

View Proceedings of Previous Conferences

Chemotherapy 2015 proceedings
cancer summit proceedings
Biomarkers 2013 Proceedings
Indo Cancer Summit Proceedings
Authorization Policy

By registering for the conference you grant permission to Conferenceseries LLC to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.